Connor, Clark & Lunn Investment Management Ltd. Veracyte, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $18.8 Billion
- Q3 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Veracyte, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 360,871 shares of VCYT stock, worth $14.3 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
360,871
Previous 92,871
288.57%
Holding current value
$14.3 Million
Previous $2.01 Million
510.34%
% of portfolio
0.07%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding VCYT
# of Institutions
308Shares Held
81.8MCall Options Held
134KPut Options Held
13.3K-
Black Rock Inc. New York, NY7.79MShares$309 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.75MShares$307 Million0.0% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI5.02MShares$199 Million0.27% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl4.92MShares$195 Million1.59% of portfolio
-
Wellington Management Group LLP Boston, MA4.23MShares$168 Million0.03% of portfolio
About VERACYTE, INC.
- Ticker VCYT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,575,904
- Market Cap $2.83B
- Description
- Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...